Iambic Therapeutics

The models are the discovery engine, not an analysis aid alongside it. Two named systems do the work: NeuralPLexer predicts protein ligand complex structures and their conformational changes, and Enchant is a multimodal transformer that learns from small noisy data sets to predict biochemical and cellular activity. The lead clinical asset was identified using the platform, which is the only proof that matters on this axis in drug discovery.

The platform generates molecular designs which are then synthesized and tested, with the company describing a high throughput experimental platform converting designs into biological insights each week. That closed loop of model proposal and wet lab verification is the oversight mechanism, and it is a strong one, but no disclosure was located on how candidate selection decisions are made between model output and synthesis, so the human decision points are inferred rather than documented.

Rare among AI drug discovery firms in submitting its core method to peer review rather than describing it in marketing terms. NeuralPLexer was published as a cover article in Nature Machine Intelligence, with reported benchmark performance on PoseBusters for the third generation, and the architectural approach is stated specifically as physics informed machine learning integrating physics principles into the AI architecture to improve data efficiency. A reviewer can read the method and evaluate the claim independently.

The strongest possible evidence class in this category is a platform derived molecule with human data, and that exists here. IAM1363 moved from program start to clinical trial initiation in a reported two years, first patient dosed March 2024, with early Phase 1/1b data presented at the 2025 ESMO Congress reporting tumor reductions in heavily pretreated patients who had exhausted standard of care. Trial NCT06253871 is registered and independently checkable. Buyers should read this as validation of the discovery platform's speed and molecule quality, not yet as clinical proof of the asset, which remains early phase.

Not applicable in the provider sense and rated accordingly rather than penalized. The platform operates on molecular and preclinical data rather than patient records; the clinical trial does involve human subjects, governed by trial protocol and site IRB rather than by vendor PHI policy. No AI specific safety framework was located.

No HIPAA or BAA posture published, and the buyer relationship does not typically require one. Partners are pharmaceutical R&D organizations contracting for discovery collaboration rather than health systems handing over patient data.

No SOC 2, ISO 27001, or equivalent attestation was located in public materials. Worth noting that partners here are handing over proprietary target and compound information rather than PHI, so a pharmaceutical partner's diligence on this axis would run through the collaboration agreement rather than a public trust page.

Regulatory engagement is real but at the asset level rather than the platform level, which is the correct structure in drug discovery: the platform itself is not a regulated device. An IND for IAM1363 was accepted by FDA, the Phase 1/1b trial is registered on ClinicalTrials.gov as NCT06253871, and the study has expanded from United States sites into the EU. A second program, a dual CDK2/4 inhibitor, is described at discovery or IND enabling stage.

No AI governance framework or model bias disclosure was located. The relevant bias question in this domain is chemical and biological rather than demographic, meaning whether training data skews the platform toward well explored target classes, and the peer reviewed benchmark disclosure partially addresses that question without being framed as governance.

Not applicable. This is a preclinical discovery platform with no provider workflow surface and no EHR touchpoint.

The commercial model is collaboration rather than software deployment. Partners access specific technologies under agreement, as with the reported grant of NeuralPLexer access to a large pharmaceutical partner, but no hosting, tenancy, or residency terms are published.

No price list exists and none would be meaningful, since the commercial surface is partnership structure rather than licensing. What is disclosed is unusually specific for a private company: a multi year collaboration with a major pharmaceutical partner carrying upfront, research cost, and technology access payments with success based milestones stated as potentially exceeding 1.7 billion dollars plus royalties on net sales. Deal shape is public even though economics per program are not.

Deliberately concentrated rather than broad. The disclosed pipeline is primarily oncology, with programs in HER2 driven cancers and cell cycle targets, plus a neurological indication described at discovery stage. The platform is claimed to work across multiple target classes and mechanisms, and the small molecule focus is explicit, so buyers outside small molecule oncology should treat applicability as unproven rather than assumed.